OBJECTIVE: To investigate antiretroviral treatment (ART) interruption in a long-term treatment cohort in South Africa. METHODS: All adults accessing ART between 2004 and 2009 were included in this analysis. Defaulting was defined as having stopped all ART drugs for more than 30 days. Treatment interrupters were patients who defaulted and returned to care during the study, whereas loss to follow-up was defined as defaulting and not returning to care. Kaplan-Meier estimates and Poisson regression models were used to analyze rates and determinants of defaulting therapy and of treatment resumption. RESULTS: Overall rate of defaulting treatment was 12.8 per 100 person-years (95% confidence interval: 11.4 to 14.4). Risk factors for defaulting were male gender, high baseline CD4 count, recency of ART initiation, and time on ART. The probability of resuming therapy within 3 years of defaulting therapy was 42% (event rate = 21.4 per 100 person-years). Factors associated with restarting treatment were female gender, older age, and time since defaulting. CONCLUSIONS: Defaulting treatment need not be an irreversible event. Interventions to increase retention in care should target men, less immunocompromised patients, and patients during the first 6 months of treatment. Resumption of treatment is most likely within the first year of interrupting therapy.
OBJECTIVE: To investigate antiretroviral treatment (ART) interruption in a long-term treatment cohort in South Africa. METHODS: All adults accessing ART between 2004 and 2009 were included in this analysis. Defaulting was defined as having stopped all ART drugs for more than 30 days. Treatment interrupters were patients who defaulted and returned to care during the study, whereas loss to follow-up was defined as defaulting and not returning to care. Kaplan-Meier estimates and Poisson regression models were used to analyze rates and determinants of defaulting therapy and of treatment resumption. RESULTS: Overall rate of defaulting treatment was 12.8 per 100 person-years (95% confidence interval: 11.4 to 14.4). Risk factors for defaulting were male gender, high baseline CD4 count, recency of ART initiation, and time on ART. The probability of resuming therapy within 3 years of defaulting therapy was 42% (event rate = 21.4 per 100 person-years). Factors associated with restarting treatment were female gender, older age, and time since defaulting. CONCLUSIONS: Defaulting treatment need not be an irreversible event. Interventions to increase retention in care should target men, less immunocompromised patients, and patients during the first 6 months of treatment. Resumption of treatment is most likely within the first year of interrupting therapy.
Authors: C Holkmann Olsen; A Mocroft; O Kirk; S Vella; A Blaxhult; N Clumeck; M Fisher; C Katlama; A N Phillips; J D Lundgren Journal: HIV Med Date: 2007-03 Impact factor: 3.180
Authors: Robert H Remien; Jenifar Chowdhury; Jacques E Mokhbat; Cherif Soliman; Maha El Adawy; Wafaa El-Sadr Journal: J Acquir Immune Defic Syndr Date: 2009-07-01 Impact factor: 3.731
Authors: Jean-Jacques Parienti; Moupali Das-Douglas; Véronique Massari; David Guzman; Steven G Deeks; Renaud Verdon; David R Bangsberg Journal: PLoS One Date: 2008-07-30 Impact factor: 3.240
Authors: Leigh F Johnson; Janne Estill; Olivia Keiser; Morna Cornell; Haroon Moolla; Michael Schomaker; Anna Grimsrud; Mary-Ann Davies; Andrew Boulle Journal: Am J Epidemiol Date: 2014-11-15 Impact factor: 4.897
Authors: Helen Bygrave; Katharina Kranzer; Katherine Hilderbrand; Jonathan Whittall; Guillaume Jouquet; Eric Goemaere; Nathalie Vlahakis; Laura Triviño; Lipontso Makakole; Nathan Ford Journal: PLoS One Date: 2010-10-08 Impact factor: 3.240
Authors: H Samji; T E Taha; D Moore; A N Burchell; A Cescon; C Cooper; J M Raboud; M B Klein; M R Loutfy; N Machouf; C M Tsoukas; J S G Montaner; R S Hogg Journal: HIV Med Date: 2014-09-01 Impact factor: 3.180